John Rossi

John Rossi

Company: Cero Therapeutics Inc.

Job title: Senior Vice President, Head of Translational Medicine


Panel Discussion: Leveraging Innate & Adaptive Systems to Open the Therapeutic Window with Novel, Rational Combinations 9:30 am

Which approach holds more potential: doubling down on T-Cell activity through combination therapy with PD-1/PD-L1 (for example), or harnessing alternative cell types such as innate immune cell engagers and gamma delta T-Cells? Evaluate the key risks and opportunities presented by each of these approaches Consider the limitations of these areas Discuss the ideal sequencing of…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.